Glaxosmsc 5.25% Regulatory News (AG99)

Issued: 22 November 2022, London UK - LSE Announcement

GlaxoSmithKline Capital plc Publication of Supplement to the Base Prospectus

GlaxoSmithKline Capital plc today announced that the following supplement dated 22 November 2022 to the base prospectus dated 7 September 2022 (as supplemented by the prospectus supplement dated 3 November 2022 and by the prospectus supplement dated 18 November 2022) has been approved by the UK Listing Authority and is available for viewing:

GSK plc, GlaxoSmithKline Capital plc, GSK Capital B.V. and GSK Capital K.K. £20,000,000,000 Euro Medium Term Note Programme

Copies of the supplement to the base prospectus and the documents incorporated by reference within it have been submitted to the National Storage Mechanism and will shortly be available for inspection at and can be downloaded from:

https://data.fca.org.uk/#/nsm/nationalstoragemechanism

For further information, please contact:

GSK plc

980 Great West Road

Brentford

Middlesex

TW8 9GS

United Kingdom

Enquiries:

BASIS ON WHICH YOU MAY ACCESS THE SUPPLEMENT TO THE BASE PROSPECTUS

Please note that the information contained in the supplement to the base prospectus may be addressed to and/or targeted at persons who are residents of particular countries (specified in the base prospectus) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the supplement to the base prospectus is not addressed. Prior to relying on the information contained in the supplement to the base prospectus you must ascertain from the supplement to the base prospectus whether or not you are part of the intended addressees of the information contained therein.

Your right to access this service is conditional upon complying with the above

About GSK GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com/company